ClinicalTrials.gg
CompletedNCT01751126Updated Mar 28, 2022Results posted

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

A Phase 3 interventional study of NOVA22007 ''Ciclosporin'' and Placebo in Vernal Keratoconjunctivitis, sponsored by Santen SAS. Completed at 46 sites in 11 countries. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
4 Years to 18 Years
Sex
All
01

Study summary

The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day in patients with severe vernal keratoconjunctivitis after 4 months of treatment.

02

Conditions studied

  • Vernal Keratoconjunctivitis

Keywords

  • vernal keratoconjunctivitis
  • ciclosporin
  • cyclosporine
03

In context

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

This study's enrollment of 169 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.

Browse Conjunctivitis, Allergic studies →

Lead sponsor

Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

First submitted after Santen Inc. became part of Santen Pharmaceutical Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females from 4 to less than 18 years of age.
  • History of at least one recurrence of vernal keratoconjunctivitis (VKC) in the past year prior to enrolment.
  • Patients not receiving any treatment for an established and active VKC; or patients already receiving treatment for their VKC provided treatment is stopped according to the specified in the exclusion criteria.
  • Active severe VKC consistent with grade 3 or 4 of Bonini scale (Bonini 2007) with severe keratitis (grade 4 or 5 on the modified Oxford scale).
  • Mean score of 4 subjective symptoms (photophobia, tearing, itching and mucous discharge) ≥ 60 mm using a 100 mm Visual Analogue Scale (where "0" means no symptom and "100" means the worst that have been ever experienced).

Exclusion criteria

Exclusion Criteria:

  • Any relevant ocular anomaly other than VKC interfering with the ocular surface including trauma, post radiation keratitis, severe blepharitis, rosacea, corneal ulcer etc.
  • Abnormal lid anatomy, abnormalities of the nasolacrimal drainage system or blinking function in either eye.
  • Active herpes keratitis or history of ocular herpes.
  • Active ocular infection (viral, bacterial, fungal, protozoal).
  • Any ocular diseases other than VKC requiring topical ocular treatment during the course of the study.
  • Contact lenses wear during the study.
  • Topical and/or systemic use of within one week prior to enrolment.
  • Topical ciclosporin (e.g. Restasis®), tacrolimus or sirolimus within 90 days prior to enrolment.
  • Scraping of the vernal plaque within one month prior to the Baseline visit.
  • Ocular surgery within 6 months prior to the Baseline visit (excluding surgical treatment of the vernal plaque).
  • Disease not stabilized within 30 days before the Baseline Visit (e.g., diabetes with glycemia out of range, thyroid malfunction, uncontrolled disease, current systemic infections) or judged by the investigator to be incompatible with the study.
  • Presence or history of severe systemic allergy.
  • Any systemic drugs within 90 days before the Baseline Visit.
  • Known to one of the components of the study or procedural medications (e.g., fluorescein, etc).
  • History of in the last 5 years.
  • Pregnancy or lactation at the Baseline Visit.
  • History of ocular varicella-zoster or vaccinia virus infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    Ciclosporin

    One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).

    Drug: NOVA22007 ''Ciclosporin''

  • Experimental
    Ciclosporin/Placebo

    One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.

    Drug: NOVA22007 ''Ciclosporin'' · Drug: Placebo

  • Placebo comparator
    Placebo

    One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).

    Drug: Placebo

Interventions

  • Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.

  • DrugPlacebo

    Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.

06

What researchers measure

Primary outcomes

  1. Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months

    Efficacy was assessed every month during the 4-month treatment phase and compared with Baseline using a composite criterion based on: * Keratitis assessed by the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5). On this modified scale, the score 0 corresponded to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represented complete corneal clearing. * Need for rescue medication. * Occurrence of corneal ulceration. An efficacy score was calculated as follows: Patient's score at month X = CFS (Baseline) - CFS (Month X) + penalty (ies) Penalty for rescue medication: -1 (per course, with a maximum of 2 courses between 2 scheduled visits) Penalty for corneal ulceration: -1 (per occurrence). A positive value indicated improvement. The maximum CFS is five and the minimum cannot be set due to the number of rescue medication and ulceration which decreases the penalty adjusted CFS.

    Time frame: over the 4 months

Secondary outcomes

  1. Best Corrected Distance Visual Acuity (BCDVA) in 4-month Randomized Period I

    Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicates poor vision.

    Time frame: Up to Month4

  2. Best Corrected Distance Visual Acuity (BCDVA) in 8-month Safety FU Period- Period II

    Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicate poor vision.

    Time frame: Up to Month12

  3. Number of Courses of Rescue Medication in Period I

    Use of rescue medication: the total number of topical corticosteroid courses was assessed at each visit during the 4-month efficacy evaluation treatment period.

    Time frame: Up to Month4

07

Results

Posted Mar 28, 2022

Participant flow

Period I
Participant flow — Period I
MilestoneHigh Dose RegimenLow Dose RegimenPlacebo
Started575458
Completed514349
Not completed6119
Period II
Participant flow — Period II
MilestoneHigh Dose RegimenLow Dose RegimenPlacebo
Started72700
Completed72700
Not completed000

Outcome measures

PrimaryAverage Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months

Efficacy was assessed every month during the 4-month treatment phase and compared with Baseline using a composite criterion based on: * Keratitis assessed by the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5). On this modified scale, the score 0 corresponded to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represented complete corneal clearing. * Need for rescue medication. * Occurrence of corneal ulceration. An efficacy score was calculated as follows: Patient's score at month X = CFS (Baseline) - CFS (Month X) + penalty (ies) Penalty for rescue medication: -1 (per course, with a maximum of 2 courses between 2 scheduled visits) Penalty for corneal ulceration: -1 (per occurrence). A positive value indicated improvement. The maximum CFS is five and the minimum cannot be set due to the number of rescue medication and ulceration which decreases the penalty adjusted CFS.

Time frame:
over the 4 months
Reported as:
Mean · Penalties Adjusted CFS Score
Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months
Penalties Adjusted CFS ScoreHigh Dose RegimenLow Dose RegimenPlacebo
Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months2.06 ± 1.441.93 ± 1.371.34 ± 1.22
Statistical analysis
  • High Dose Regimen vs Placebo · t-test, 2 sided · p = 0.007 (ANCOVA with treatment as well as the baseline CFS and the exposure to Vernal keratoconjunctivitis (VKC) seasons (Hochberg procedure).) · Ls mean: 0.76 · 95% CI 0.26 to 1.27
  • Low Dose Regimen vs Placebo · ANCOVA · p = 0.010 · Ls mean: 0.67 · 95% CI 0.16 to 1.18ANCOVA with treatment as well as the baseline CFS and the exposure to Vernal keratoconjunctivitis (VKC) seasons (Hochberg procedure).
SecondaryBest Corrected Distance Visual Acuity (BCDVA) in 4-month Randomized Period I

Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicates poor vision.

Time frame:
Up to Month4
Reported as:
Mean · letters
Best Corrected Distance Visual Acuity (BCDVA) in 4-month Randomized Period I
lettersLogMAR - High Dose RegimenLogMAR - Low Dose RegimenLogMAR-PlaceboChange From Baseline in LogMAR- High DoseChange From Baseline in LogMAR- Low DoseChange From Baseline in LogMAR- Placebo
Analysis Eye-Baseline0.293 ± 0.2970.209 ± 0.2840.302 ± 0.3470 ± 00 ± 00 ± 0
Analysis Eye-Month 10.263 ± 0.2920.160 ± 0.2410.285 ± 0.362-0.036 ± 0.187-0.058 ± 0.199-0.027 ± 0.182
Analysis Eye-Month 20.221 ± 0.2510.146 ± 0.2140.331 ± 0.352-0.071 ± 0.191-0.073 ± 0.2020.003 ± 0.233
Analysis Eye-Month 30.172 ± 0.2350.110 ± 0.2040.273 ± 0.318-0.110 ± 0.173-0.089 ± 0.233-0.066 ± 0.229
Analysis Eye-Month 40.149 ± 0.2440.097 ± 0.2030.237 ± 0.308-0.127 ± 0.165-0.110 ± 0.233-0.109 ± 0.211
Analysis Eye-Month 4/ Early Termination0.158 ± 0.2490.114 ± 0.2120.217 ± 0.295-0.135 ± 0.220-0.091 ± 0.257-0.097 ± 0.210
SecondaryBest Corrected Distance Visual Acuity (BCDVA) in 8-month Safety FU Period- Period II

Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicate poor vision.

Time frame:
Up to Month12
Reported as:
Mean · letters
Best Corrected Distance Visual Acuity (BCDVA) in 8-month Safety FU Period- Period II
lettersLogMAR - High Dose RegimenLogMAR - PlaceboLogMAR-TotalChange From Baseline in LogMAR- High DoseChange From Baseline in LogMAR- PlaceboChange From Baseline in LogMAR- Total
Analysis Eye-Baseline (Month 4)0.152 ± 0.2460.250 ± 0.3170.181 ± 0.2700 ± 00 ± 00 ± 0
Analysis Eye-Month 60.128 ± 0.2300.258 ± 0.3590.168 ± 0.280-0.024 ± 0.114-0.017 ± 0.143-0.022 ± 0.122
Analysis Eye-Month 80.141 ± 0.2280.222 ± 0.3240.165 ± 0.261-0.015 ± 0.136-0.029 ± 0.155-0.019 ± 0.141
Analysis Eye-Month 100.141 ± 0.2220.207 ± 0.3250.160 ± 0.257-0.014 ± 0.149-0.044 ± 0.128-0.023 ± 0.143
Analysis Eye-Month 120.134 ± 0.2140.220 ± 0.3630.160 ± 0.268-0.020 ± 0.152-0.030 ± 0.172-0.023 ± 0.157
Analysis Eye-Month 12/ Early Termination0.136 ± 0.2120.220 ± 0.3630.161 ± 0.266-0.016 ± 0.154-0.030 ± 0.172-0.020 ± 0.158
SecondaryNumber of Courses of Rescue Medication in Period I

Use of rescue medication: the total number of topical corticosteroid courses was assessed at each visit during the 4-month efficacy evaluation treatment period.

Time frame:
Up to Month4
Reported as:
Count of participants · Participants
Number of Courses of Rescue Medication in Period I
ParticipantsHigh Dose RegimenLow Dose RegimenPlacebo
Month1, zero course514144
Month 1, one course3711
Month1, two courses022
Month2, zero course454338
Month 2, one course6211
Month 2, two courses223
Month3, zero course434234
Month3, one course7212
Month 3, two courses124
Month4, zero course424138
Month4, one course628
Month 4, two courses212
Month 4/Early Termination, zero course464643
Month 4/Early Termination, one course7511
Month 4/Early Termination, two courses334

Adverse events

Collected over From the time the informed consent form was signed until the last study visit at Month 12.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
.1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)—3/50 (6%)29/50 (58%)
Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)—0/22 (0%)13/22 (59.1%)
Total High Dose—3/72 (4.2%)42/72 (58.3%)
.1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)—1/44 (2.3%)24/44 (54.5%)
Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)—0/26 (0%)11/26 (42.3%)
Total Low Dose—1/70 (1.4%)35/70 (50%)
Most frequent serious events
Most frequent serious events
Event.1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)Total High Dose.1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)Total Low Dose
Head injuryInjury, poisoning and procedural complications0/500/220/721/440/261/70
Tibia fractureInjury, poisoning and procedural complications1/500/221/720/440/260/70
Ulcerative keratitisEye disorders1/500/221/720/440/260/70
PhimosisCongenital, familial and genetic disorders1/500/221/720/440/260/70
Most frequent other events
Showing 10 of 87
Most frequent other events
Event.1% QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)Vehicle QID (4 Months) Plus .1% QID (8 Months Safety Follow-up)Total High Dose.1% BID + Vehicle BID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)Vehicle QID (4 Months) Plus .1% BID+ Vehicle BID (8 Months Safety Follow-up)Total Low Dose
Instillation site painGeneral disorders6/504/2210/725/440/265/70
Eye pruritusEye disorders0/503/223/720/441/261/70
Instillation site pruritusGeneral disorders2/503/225/724/440/264/70
NasopharyngitisInfections and infestations3/500/223/725/441/266/70
Ocular hyperaemiaEye disorders2/502/224/720/441/261/70
Ocular discomfortEye disorders0/502/222/720/440/260/70
Instillation site erythemaGeneral disorders1/502/223/722/440/262/70
InfluenzaInfections and infestations4/500/224/720/440/260/70
HeadacheNervous system disorders4/501/225/720/441/261/70
PharyngitisEye disorders2/500/222/720/442/262/70

Baseline characteristics

One participant from the High dose regimen withdrew at the first week of randomization and not related to study medication.

Age, Customized
Age, Customized(years)High Dose RegimenLow Dose RegimenPlaceboTotal
Children (4-18 years)9.1 ± 3.39.6 ± 3.48.9 ± 3.29.2 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)High Dose RegimenLow Dose RegimenPlaceboTotal
Female12121236
Male444246132
Race (NIH/OMB)
Race (NIH/OMB)(Participants)High Dose RegimenLow Dose RegimenPlaceboTotal
American Indian or Alaska Native0000
Asian11111335
Native Hawaiian or Other Pacific Islander0000
Black or African American35210
White403841119
More than one race0000
Unknown or Not Reported2024
08

Study locations

46 sites
  • Glendale, CA, USA
    Glendale, California 91204, United States
  • Irvine, CA, USA
    Irvine, California 92697, United States
  • Rancho Cordova, CA, USA
    Rancho Cordova, California 95670, United States
  • Miami, FL, USA
    Miami, Florida 33136, United States
  • Zagreb, City of Zagreb, HR
    Zagreb, City Of Zagreb 10000, Croatia
  • Marseille, Bouches-du-Rhône, FR
    Marseille, Bouches-du-Rhône 13008, France
  • Angers CEDEX 9, Maine-et-Loire, FR
    Angers CEDEX 9, Maine-et-Loire 49933, France
  • Amiens CEDEX, Somme, FR
    Amiens CEDEX, Somme 80054, France
  • Tours CEDEX 9, FR
    Tours, 37044, France
  • Paris CEDEX 8, Île-de-France, FR
    Paris CEDEX 8, Île-de-France 75877, France
  • Mainz, Rhineland-Palatinate, DE
    Mainz, Rhineland-Palatinate 55131, Germany
  • Ioannina, Eprius, GR
    Ioannina, Eprius 45500, Greece
  • Thessaloniki, Macedonia, GR
    Thessaloniki, Macedonia 54636, Greece
  • Larissa, Thessaly, GR
    Larissa, Thessaly 41110, Greece
  • Szeged, Csongrád, HU
    Szeged, Csongrád H-6720, Hungary
  • Debrecen, Hajdú-Bihar, HU
    Debrecen, Hajdú-Bihar H-4031, Hungary
  • Budapest, HU
    Budapest, H-1085, Hungary
  • Visakhapatnam, Andhra Pradesh, IN
    Visakhapatnam, Andhra Pradesh 530013, India
  • New Delhi, National Capitol Territory, IN
    New Delhi, National Capitol Territory 110002, India
  • Chennai, Tamil Nadu, IN
    Chennai, Tamil Nadu 600006, India
  • Lucknow, Uttar Pradesh, IN
    Lucknow, Uttar Pradesh 226003, India
  • Be'er-Sheva, IL
    Be'er-Sheva, 84101, Israel
  • Jerusalem, IL
    Jerusalem, 91120, Israel
  • Petah-Tikva, IL
    Petah-Tikva, 49100, Israel
  • Rehovot, IL
    Rehovot, 76100, Israel
  • Tel-Aviv, IL
    Tel-Aviv, 64239, Israel
  • Bologna, Emilia-Romagna, IT
    Bologna, Emilia-Romagna 40138, Italy
  • Lavagna, Liguria, IT
    Lavagna, Liguria 16033, Italy
  • Cinisello, Pisa, IT
    Cinisello, Pisa 56124, Italy
  • Firenze, Tuscany, IT
    Firenze, Tuscany 50139, Italy
  • Padova, Veneto, IT
    Padova, Veneto 35128, Italy
  • Messina, Messina, IT
    Messina, 98125, Italy
  • Vila Nova de Gaia, Douro Litoral, PT
    Vila Nova de Gaia, Douro Litoral 4434-502, Portugal
  • Lisboa, Extremadura, PT
    Lisboa, Extremadura 1150-199, Portugal
  • Lisboa, Extremadura, PT
    Lisboa, Extremadura 1169-019, Portugal
  • Torrevieja, Alicante, ES
    Torrevieja, Alicante 03186, Spain
  • Barakaldo, Biscay, ES
    Barakaldo, Biscay 48903, Spain
  • San Sebastián, Guipúzcoa, ES
    San Sebastián, Guipúzcoa 20014, Spain
  • Aranjuez, Madrid, ES
    Aranjuez, Madrid 28300, Spain
  • A Coruña, A Coruña, ES
    A Coruña, 15006, Spain
  • Alicante, Alicante, ES
    Alicante, 03016, Spain
  • Madrid, Madrid, ES
    Madrid, 28009, Spain
  • Madrid, Madrid, ES
    Madrid, 28046, Spain
  • Sevilla, Sevilla, ES
    Sevilla, 41003, Spain
  • Valencia, Valencia, ES
    Valencia, 46014, Spain
  • Valencia, Valencia, ES
    Valencia, 46015, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2022, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 17, 2012
Start
Apr 29, 2013
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Mar 28, 2022
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01751126
Lead sponsor
Santen SAS
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Apr 29, 2013
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Mar 28, 2022
Last update
Mar 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NOVA22007

Start the discussion